VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, January 5, 2026
Stock Comparison
Emerson Electric Co. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Emerson Electric Co.
EMR · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Emerson Electric Co.'s moat claims, evidence, and risks.
View EMR analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 70 / 100 for Emerson Electric Co.).
- Segment focus: Emerson Electric Co. has 6 segments (24.2% in Final Control); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Emerson Electric Co. has 10 moat types across 4 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Emerson Electric Co.
Final Control
Industrial control valves, isolation/shutoff valves, pressure relief & safety valves, actuators and regulators
Global
Process & hybrid manufacturers
Automation components supplier
24.2%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Emerson Electric Co. strengths
Gilead Sciences, Inc. strengths
Segment mix
Emerson Electric Co. segments
Full profile >Final Control
Oligopoly
Measurement & Analytical
Oligopoly
Discrete Automation
Competitive
Safety & Productivity
Competitive
Control Systems & Software
Oligopoly
Test & Measurement
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.